MediLink

Beyond's analysis on MediLink

• 2026-09-13 — MediLink's interim phase III data show Tambotatug pelitecan improves overall survival in relapsed small-cell lung cancer, bolstering Roche's oncology prospects in China

Recent news mentioning MediLink

• 2026-09-13 — Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer

Appears alongside

• Roche
• III
• Tam-Peli

Browse the full archive →